Clinical trials: Macroprolactinoma
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Macroprolactinoma
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
To study the effects of rapid escalation of Cabergoline in comparison to conventional dosing in macroprolactinomas. Rapid escalation of cabergoline may help in earlier normalization of prolactin and shrinkage of tumor mass, and…
- Trial name
- NCT01143584
- Testing
- Cabergoline
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University